Orphan Designation: An Overview by EMA

There are over 6,000 different rare diseases identified to date that affect 3.5% – 5.9% of the worldwide population. They have a big impact not only on the person diagnosed, but also on their families, friends, care takers and society as a whole.

This is why development of medicines addressing rare diseases, also known as orphan medicines, is crucial.

Don’t miss out the video created by the European Medicines Agency (EMA) to learn how EMA supports the development of orphan medicines to treat rare diseases in the European Union.

Watch the video: here.